MapLight Therapeutics, Inc. Common Stock (MPLT)vsRevolution Medicines Inc (RVMD)
MPLT
MapLight Therapeutics, Inc. Common Stock
$10.92
-3.53%
HEALTHCARE · Cap: $528.71M
RVMD
Revolution Medicines Inc
$190.95
-3.04%
HEALTHCARE · Cap: $44.44B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. MPLT earns a higher WallStSmart Score of 29/100 (F).
MPLT
Avoid29
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 15.7x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MPLT
The strongest argument for MPLT centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : MPLT
The primary concerns for MPLT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
MPLT is growing revenue faster at 0.0% — sustainability is the question.
MPLT generates stronger free cash flow (-45M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MPLT scores higher overall (29/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MapLight Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
MapLight Therapeutics, Inc. is an innovative biotechnology company that is dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders. Utilizing a proprietary platform, MapLight focuses on intricate biological pathways to create transformative treatment solutions aimed at significantly enhancing patient outcomes. With a robust commitment to scientific rigor and a promising clinical pipeline, the company is strategically positioned to meet critical unmet medical needs, establishing itself as a potential leader in the dynamic neurotherapeutics sector.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?